HK Stock Market Move | 3SBIO (01530) is now up more than 6%, Pfizer has identified 707 as a core pipeline and plans to initiate multiple clinical studies.

3SBIO (01530) is now up over 6%, rising by 6.26% to HKD 32.58 at the time of writing, with a turnover of HKD 4.13 billion. On the news front, 3SBIO announced the phase 2 clinical study data of 707 combination chemotherapy for 1LNSCLC at the 2025 STIC conference. In addition, Pfizer disclosed its global clinical strategy for 707. After reaching an agreement with 3SBIO, Pfizer is actively advancing the clinical development of 707 and has listed the 707 pipeline as its core pipeline. Currently, five new clinical applications have been submitted, and Pfizer's second wave development plan is expected to add 10 clinical trials for new indications and over 10 novel combination schemes by the end of 2026. Guosen released a research report stating that the company's innovative drugs are advancing rapidly in clinical trials, completing major external licensing transactions, and maintaining steady growth in performance. Considering the successful external licensing of 707, we have raised our profit forecast and expect the company's net profit attributable to equity holders to be RMB 9.955 billion, RMB 2.875 billion, and RMB 3.212 billion in 2025-2027. 3SBIO's core products are advancing rapidly in global clinical development, maintaining a rating of "outperform the market".